Search Results - "Shepherd, LE"

HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy by Pritchard, Kathleen I, Shepherd, Lois E, O'Malley, Frances P, Andrulis, Irene L, Tu, Dongsheng, Bramwell, Vivien H, Levine, Mark N

“…Women with breast cancer in which the HER2 gene was amplified had a better response to adjuvant treatment with an anthracycline-containing regimen than to a…”
Get full text

Abstract P5-07-01: LncRNA MIR2052HG regulates ERα level and endocrine resistance through LMTK3 by recruiting early growth response protein 1 by Cairns, J, Ingle, JN, Shepherd, LE, Kubo, M, Goetz, MP, Weinshilboum, RM, Kalari, KR, Wang, L

“…Abstract BACKGROUND: A GWAS for the MA.27 aromatase inhibitors (AIs) adjuvant trial (4,406 controls and 252 cases) identified variant (V) SNPs in a long…”
Get full text

Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer by Ribic, Christine M, Sargent, Daniel J, Moore, Malcolm J, Thibodeau, Stephen N, French, Amy J, Goldberg, Richard M, Hamilton, Stanley R, Laurent-Puig, Pierre, Gryfe, Robert, Shepherd, Lois E, Tu, Dongsheng, Redston, Mark, Gallinger, Steven

“…In some colorectal cancers, a loss of DNA-repair function causes a defect called microsatellite instability. This study unexpectedly found that adjuvant…”
Get full text

Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? by GILL, Sharlene, LOPRINZI, Charles L, LABIANCA, Roberto, WEI CHEN, CHA, Stephen S, HELDEBRANT, Michael P, GOLDBERG, Richard M, SARGENT, Daniel J, THOME, Stephan D, ALBERTS, Steven R, HALLER, Daniel G, BENEDETTI, Jacqueline, FRANCINI, Guido, SHEPHERD, Lois E, SEITZ, Jean Francois

“…Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the…”
Get full text

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer by Goss, Paul E, Ingle, James N, Martino, Silvana, Robert, Nicholas J, Muss, Hyman B, Piccart, Martine J, Castiglione, Monica, Tu, Dongsheng, Shepherd, Lois E, Pritchard, Kathleen I, Livingston, Robert B, Davidson, Nancy E, Norton, Larry, Perez, Edith A, Abrams, Jeffrey S, Therasse, Patrick, Palmer, Michael J, Pater, Joseph L

“…Postmenopausal women with early breast cancer who have undergone successful initial therapy receive five years of treatment with tamoxifen, an antagonist of…”
Get full text

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 by Strasser-Weippl, K., Sudan, G., Ramjeesingh, R., Shepherd, L.E., O'Shaughnessy, J., Parulekar, W.R., Liedke, P.E.R., Chen, B.E., Goss, P.E.

“…Histological subtype, (invasive ductal breast cancer (IDBC)/invasive lobular breast cancer (ILBC)), might be a marker for differential response to endocrine…”
Get full text

Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial by Moku, PR, Shepherd, LE, Ali, SM, Leitzel, K, Parulekar, WE, Zhu, L, Virk, S, Nomikos, D, Aparicio, S, Gelmon, KA, Drabick, JJ, Cream, L, Halstead, SE, Umstead, T, Mckeone, D, Maddukuri, A, Polimera, HV, Ali, A, Poulose, J, Pancholy, N, Spiegel, H, Nagabhairu, V, Chen, BE, Lipton, A

“…Abstract Background: In the CCTG (Canadian Clinical Trials Group) MA.31 randomized phase 3 trial, the trastuzumab-taxane combination led to longer PFS than…”
Get full text

Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group by MEYER, Ralph M, GOSPODAROWICZ, Mary K, DJURFELDT, Marina S, KEYUE DING, SHEPHERD, Lois E, CONNORS, Joseph M, PEARCEY, Robert G, BEZJAK, Andrea, WELLS, Woodrow A, BURNS, Bruce F, WINTER, Jane N, HORNING, Sandra J, DAR, A. Rashid

“…We report results of a randomized trial comparing ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy alone with treatment that includes…”
Get full text

A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients by Sargent, Daniel J, Goldberg, Richard M, Jacobson, Stacy D, Macdonald, John S, Labianca, Roberto, Haller, Daniel G, Shepherd, Lois E, Seitz, Jean François, Francini, Guido

“…After successful surgery for colorectal cancer, patients over 70 years of age are less likely to receive postoperative (adjuvant) chemotherapy than younger…”
Get full text

Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 by LEVINE, Mark N, PRITCHARD, Kathleen I, BRAMWELL, Vivien H. C, SHEPHERD, Lois E, DONGSHENG TU, PAUL, Nancy

“…Certain anthracycline-containing adjuvant chemotherapy regimens are associated with improved relapse-free survival (RFS) and overall survival (OS) compared…”
Get full text

Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women by WHELAN, Timothy J, GOSS, Paul E, MARTINO, Silvana, MUSS, Hyman B, INGLE, James N, PATER, Joseph L, DONGSHENG TU, PRITCHARD, Kathleen, SHIFANG LIU, SHEPHERD, Lois E, PALMER, Michael, ROBERT, Nicholas J

“…To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen on quality of life (QOL) in the MA.17 trial. Patients completed the Short…”
Get full text

Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14 by LIPTON, Allan, CHAPMAN, Judy-Anne W, DEMERS, Laurence, SHEPHERD, Lois E, LEI HAN, WILSON, Carolyn F, PRITCHARD, Kathleen I, LEITZEL, Kim E, ALI, Suhail M, POLLAK, Michael

“…We investigated the association of bone-only relapse with a pretreatment marker of bone resorption: serum beta C-terminal telopeptide (B-CTx) of type I…”
Get full text

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial by O’Malley, F. P., Chia, S., Tu, D., Shepherd, L. E., Levine, M. N., Huntsman, D., Bramwell, V. H., Andrulis, I. L., Pritchard, K. I.

“…Overexpression of topoisomerase II protein (topo 2α) is postulated to be more closely associated with responsiveness to anthracycline-containing chemotherapy…”
Get full text

S6-2: Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole by Wagner, LI, Zhao, F, Chapman, J-AW, Cella, D, Shepherd, LE, Sledge, GW, Goss, PE

“…Abstract Background: Patient-reported outcomes (PRO) assess symptom burden and health-related quality of life (HRQL) more accurately than clinical report. We…”
Get full text

P2-14-02: NCIC CTG MA.27: Clinical Tolerability and Overall Survival of Racial and Ethnic Minority Women on Aromatase Inhibitor Therapy by Moy, B, Shepherd, LE, Chapman, J-AW, Le, Maitre A, Gelmon, KA, Elliott, C, Ingle, JN, Goss, PE

“…Abstract Background Aromatase inhibitors (AIs) are standard adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer. We…”
Get full text

P1-06-08: Effect of Treatment Emergent Symptoms on Relapse Free Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women in Early Breast Cancer by Chapman, J-AW, Shepherd, LE, Le Maitre, A, Pritchard, KI, Graham, BC, Gelmon, KA, Bramwell, VH

“…Abstract Background: Evidence from the ATAC trial that vasomotor or joint symptomatology by 3 months is associated with reduced recurrence after 3 months led…”
Get full text

Abstract P1-07-13: Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-treated NCIC CTG MA.14 patients by Chapman, J-AW, Sgroi, D, Goss, PE, Richardson, E, Binns, SN, Zhang, Y, Schnabel, CA, Erlander, MG, Pritchard, KI, Han, L, Shepherd, LE, Pollak, MN

“…Abstract Background: Poor inter-laboratory comparability of common clinically used breast cancer biomarkers led to a proposal of statistical standardization…”
Get full text

P1-06-07: TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients by Hertel, PB, Tu, D, Ejlertsen, B, Jensen, M-B, Balslev, E, Jiang, S, O'Malley, FP, Pritchard, KI, Shepherd, LE, Bartels, A, Brünner, N, Nielsen, TO

“…Abstract Purpose: HER2 amplification, TOP2A aberrations and absence of TIMP-1 (Tissue Inhibitor of Metalloproteinase-1) expression in breast carcinomas have…”
Get full text

Abstract PD03-04: Effects of Diabetes (DM), Hypertension (HTN) and Coronary Artery Disease (CAD) on Prognosis after 5 Years of Adjuvant Tamoxifen (TAM) and on Treatment Outcomes with the Use of Extended Letrozole (LET): NCIC CTG MA.17 by Goodwin, RA, Jamal, R, Booth, CM, Goss, PE, Eisenhauer, EA, Tu, D, Shepherd, LE

“…Abstract Background: Women with early stage breast cancer and DM have poorer survival compared to non-DM women (Lipscombe 2008). Mechanisms include insulin…”
Get full text

Abstract P2-13-02: Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27 by Higgins, MJ, Chapman, J-AW, Ingle, JN, Sledge, G, Budd, GT, Ellis, MJ, Pritchard, KI, Clemons, M, Badovinac, Crnjevic T, Han, L, Gelmon, K, Rabaglio, M, Elliott, C, Shepherd, LE, Goss, PE

“…Abstract Background: ASP is hypothesized to decrease the risk of breast cancer (BRCA) and BRCA recurrences. Thus we performed an exploratory analysis of ASP…”
Get full text